Filamentous cytoplasmic inclusions are hallmarks of Alzheimer disease (AD) and Pick disease (PD). Although previous studies show elevated zinc (Zn) in AD brain, there has been little study of zinc transporter (ZnT) proteins that are critical in the maintenance of Zn homeostasis. Using Western blot analysis, we show significantly elevated ZnT-6, the protein responsible for sequestration of Zn in the trans-Golgi network, in the hippocampus/ parahippocampal gyrus (HPG) of AD subjects compared to agematched controls and a trend toward elevated ZnT-6 in subjects with amnestic mild cognitive impairment (MCI). Based on these data, we used immunohistochemistry to investigate the cellular distribution of ZnT-6 in the HPG of control subjects and subjects with MCI, AD, and PD. Comparison of immediately adjacent serial sections stained using the modified Bielschowsky method and immunostained for ZnT-6 showed elevated ZnT-6 in 89 T 7% of neurofibrillary tangle (NFT)-bearing neurons in AD and 100 T 19% of Pick bodies in PD specimens. Confocal microscopy of HPG from MCI subjects double labeled for ZnT-6 and MC-1, a marker of early NFT formation, showed 85 T 4% of MC-1-positive cells were strongly ZnT-6-positive. Increased ZnT-6 immunostaining in neurons containing cytoplasmic inclusions in MCI, AD, and PD suggests a role for ZnT-6 in the pathogenesis of these lesions.
INTRODUCTION
Zinc (Zn) is an essential trace element (1, 2) that is redox inert with structural, catalytic, and regulatory roles (1Y 3) and functions as a crucial component in over 300 enzymes and transcription factors. In addition to its essential roles, several studies show that elevated Zn is toxic to cultured neurons (4 Y 6) and that there are significant elevations of Zn in the AD brain (7Y 13).
In general, maintenance of Zn homeostasis is mediated by three families of proteins: a) metallothioneins I to IV (14) that bind Zn; b) zinc regulated transporter/iron regulated transporter (ZRT/IRT)-like proteins (ZIP) that mediate Zn influx into cells (reviewed [15] ); and c) Zn transporter (ZnT) proteins ZnT-1 through ZnT-7 that remove excess intracellular Zn to the extracellular space or sequester Zn in subcellular organelles (reviewed [16] ). Although there have been several studies of metallothioneins in AD (reviewed [17] ), there has been little study of ZIP or ZnT proteins in human brain or in neuropathologic disorders.
Zinc transporter proteins 1 to 7 are members of the cation diffusion facilitator family and function to transport Zn out of cells (ZnT-1) or by sequestering Zn into intracellular compartments during periods of elevated cytoplasmic Zn (ZnT-2 through ZnT-7) (18 Y 21) . These proteins are predicted to have similar structures including six transmembrane domains and a histidine rich cytoplasmic loop between transmembrane domains IV and V. Of the seven ZnT proteins, ZnT-1, ZnT-3, ZnT-4 and ZnT-6 are expressed in brain (16) . Our previous Western blot analysis of ZnT-1 showed significantly decreased ZnT-1 levels in the hippocampus/parahippocampal gyrus (HPG) of subjects with amnestic mild cognitive impairment (MCI) and significant elevations of ZnT-1 in early and late stage AD (LAD) subjects compared to age-matched controls. To determine if alterations of other ZnT proteins are present in AD, we carried out Western blot and immunohistochemical analyses of ZnT-6 in the HPG of MCI, AD and age-matched control subjects and in the HPG of Pick disease (PD) subjects as another tauopathy. ZnT-6 is of particular interest in AD because it functions to sequester Zn in the trans-Golgi network (TGN), a likely site of amyloid beta peptide (AA) generation through cleavage of the amyloid precursor protein by the proteolytic gamma secretase complex (22, 23) .
MATERIALS AND METHODS

Case Selection and Neuropathologic Examination
For Western blot analysis specimens of HPG were obtained from short postmortem interval (PMI) autopsies of 8 subjects with AD (5M, 3F), 6 subjects with MCI (3M, 3F) and 5 age-matched control subjects (4M, 1F). Samples were immediately frozen in liquid nitrogen and subsequently stored at j80-C until used for analysis. For immunohistochemical studies, serial sections of paraffin-embedded HPG were obtained from 5 AD (3M, 2F), 4 PD (3M, 1F), 5 subjects with MCI (1M, 4F), and 5 aged normal control subjects (3M, 2F) through the neuropathology core of the University of Kentucky Alzheimer's Disease Center (UK-ADC). Specimens used for Western blot analysis and immunohistochemistry were not necessarily from the same set of subjects due to limited availability of frozen specimens. All AD subjects had annual mental status testing and physical and neurological examinations, demonstrated progressive intellectual decline and met NINCDS-ADRDA Workgroup criteria for the clinical diagnosis of probable AD (24) .
Control subjects were followed longitudinally in the normal control clinic of the UK-ADC and had neuropsychologic testing annually and physical examinations biannually. All control subjects had neuropsychologic scores in the normal range and showed no evidence of memory decline. Subjects with amnestic MCI were derived from the control group and were followed longitudinally in the UK-ADC clinic. All MCI patients were normal on enrollment into the longitudinal study and developed MCI during follow-up. The clinical criteria for diagnosis of amnestic MCI were those of Petersen et al (25) and included: a) memory complaints, b) abnormal memory impairment for age and education, c) normal general cognitive function, d) intact activities of daily living, and e) the subject did not meet criteria for dementia. Objective memory test impairment was based on a score of e 1.5 standard deviations from the mean of controls on the CERAD Word List Learning Task (26) and corroborated in some cases with the Free and Cued Selective Reminding Test.
Histopathologic examination of multiple sections of neocortex, hippocampus, entorhinal cortex, amygdala, basal ganglia, thalamus, nucleus basalis of Meynert, midbrain, pons, medulla, and cerebellum using hematoxylin and eosin and the modified Bielschowsky stains along with 10D-5 (for AA) and >-synuclein immunochemistry were carried out on all subjects. All AD patients met accepted criteria for the histopathologic diagnosis of AD (27, 28) and typically demonstrated Braak scores of VI.
Histopathologic examination of control subjects showed only age-associated changes and Braak staging scores of I to II. Control subjects met the NIA-Reagan Institute low likelihood criteria for the histopathologic diagnosis of AD. MCI subjects demonstrated only age-associated brain gross changes. Braak staging scores were II to V. The major difference between normal controls and MCI patients was a significant increase in neuritic plaques in neocortical regions and an increase in NFTs in amygdala, hippocampus, and entorhinal cortex (29) .
All PD patients showed typical clinical features of frontotemporal dementia (personality, emotional and behavioral alterations, decline in executive function, and subsequent language changes). Frontal and temporal lobe atrophy was observed at autopsy and microscopic examination showed neuron loss, abundant Pick bodies, and in most cases rare balloon neurons. Demographic data for all subjects in the study are shown in Tables 1 and 2 .
ZnT-6 Antibody Characterization and Western Blot Analysis
A custom rabbit polyclonal antibody raised against amino acids 437 to 449 (QGLRTGFTNDSR) of human ZnT-6 was prepared by Chemicon International (Temecula, CA). For Western blot characterization of the antibody, a representative AD HPG specimen was homogenized in 10 mM HEPES buffer containing 137 mM NaCl, 4.6 mM KCl, 0.6 mM MgSO 4 , 0.7 Kg/mL leupeptin, 0.5 Kg/mL aprotinin and 40 Kg/mL PMSF using a Dounce homogenizer on ice. The resultant homogenate was centrifuged at 100,000 Â g for 1 hour at 4-C. The supernatant was removed and used for ZnT-6 analysis. Protein specimens (20 Kg) were separated on 10% SDS-polyacrylamide gels and transferred to nitrocellulose membranes. The membranes were blocked for 1 hour in 5% dry milk in Tris-buffered saline containing 0.05% Tween 20 (TTBS) and incubated overnight with antiZnT-6 at a dilution of 1:2500 in 5% dry milk/TTBS. The blots were washed 3 to 5 times with TTBS and incubated 2 hours with horseradish peroxidase conjugated goat antirabbit IgG (Vector Laboratories, Burlingame CA) at room temperature. The blots were washed 3 times with TTBS and bands visualized using enhanced chemiluminescence (ECL) (Amersham Biosciences, Piscataway, NJ) per manufacturer's instructions. After development, the membranes were stripped and reprobed with anti-GAPDH (Santa Cruz Biotechnology, Santa Cruz, CA; 1:5000 dilution) as a loading control. To verify specificity of the antibody, representative blots were incubated in antibody that had been incubated overnight with 1 mg immunizing peptide. For comparison of AD, MCI and control subjects, samples were prepared as described above and 5 controls and 6 to 8 AD or MCI specimens analyzed on the same gel. Band intensities were quantified using Scion Image Analysis software. Results are expressed as mean T SEM percent of control band intensity for each gel.
Immunohistochemical Staining and Quantitative Comparisons
To visualize the cellular distribution of ZnT-6, serial sections (10 Km) of paraffin-embedded HPG from 5 AD, 
4 PD, 5 MCI, and 5 aged normal control subjects were cut using a Shandon Finesse microtome (Thermo Electron, Waltham, MA), placed on Plus-slides and rehydrated through xylene, descending alcohols, and water. Section 1 of the series for AD, PD, and control subjects was stained using the modified Bielschowsky method. For ZnT-6 immunohistochemistry, the adjacent sections were rehydrated to water and incubated for 10 minutes in a 0.75 mg/mL trypsin type II (Thermo Electron, Waltham, MA) solution prepared in 150 mM Tris HCl (pH 7.6) containing 3.3 mM CaCl 2 at 37-C. The sections were allowed to air dry and were then incubated in 50 mM ammonium chloride at room temperature for 30 minutes. Following 3 rinses in PBS, the sections were immunostained using the Dako Envision System (Dako, Carpinteria, CA) per manufacturer's instructions. Briefly, endogenous peroxidase activity was blocked by incubation for 5 minutes in 3% hydrogen peroxide/methanol. Following 3 washes in water and Tris buffered saline containing 0.1% Tween-20-TTBS, the sections were incubated for 30 minutes in a 1:100 dilution of ZnT-6 in TBS containing 1% fetal bovine serum. Following 3 to 5 washes in 0.1% Tween-20-TTBS, the sections were incubated in peroxidase labeled polymer conjugated to goat anti-rabbit IgG in Tris-HCl for 30 minutes. The sections were then washed 5 times in 0.1% Tween-20-TTBS and color developed using diaminobenzidine (DAB) provided in the kit. Sections were counterstained with hematoxylin and eosin, dehydrated through graded ascending alcohols and xylene, and coverslipped. For confocal microscopy, sections of MCI HPG were treated as described above with modification. Following rehydration, treatment with trypsin and ammonium chloride, the sections were incubated overnight at 4-C in a 1:100 dilution of mouse anti->-tubulin (Sigma Chemical, St. Louis, MO) followed by incubation for 1 hour in a 1:1000 dilution of Alexa-633 conjugated anti-mouse IgG (Molecular Probes, Eugene, OR). Following thorough washing with TBS containing 0.1% Tween-20 (TTBS) the sections were incubated overnight in a 1:100 dilution of ZnT-6 and a 1:100 dilution of MC-1, a conformation-dependent monoclonal antibody that recognizes distinct pathologic confirmations of tau (30) observed only in AD brain (31) and identifies early NFT formation (31) (kindly provided by Dr. Peter Davies). Additional sections were incubated in a 1:100 dilution of anti-ZnT-6 and a 1:100 dilution of monoclonal anti trans-Golgi network (TGN-38, Affinity BioReagents, Golden, CO) to verify the subcellular localization of ZnT-6. All primary antibody solutions were prepared in TBS containing 1% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA). Following thorough rinsing in 0.1% Tween-20-TTBS, the sections were incubated 1 hour with a 1:1000 dilution of Alexa-488 conjugated anti-rabbit and Alexa-568 conjugated anti-mouse secondary antibodies (Molecular Probes, Eugene, OR) prepared in TBS containing 1% FBS. After 5 rinses in 0.1% Tween-20-TTBS and distilled/deionized water, the sections were coverslipped using fluorescent anti-fade (Molecular Probes) and imaged using a Leica DM IRBE confocal microscope equipped with argon, krypton and HeNe lasers and a 40X oil objective.
Confocal images were captured from a single z plane without optical sectioning.
To verify specificity of the ZnT-6 antibody for immunohistochemistry, serial sections of HPG from a representative AD subject were immunostained using the antibody as described above and also using antibody that had been pre-incubated with immunizing peptide for 24 hours.
Counts of NFTs and Pick bodies were performed as previously described (32) . Briefly, serial photographs of immediately adjacent Bielschowsky-stained sections and ZnT-6-immunostained sections of all of the CA1 and subiculum of each case were taken using a 20Â objective on a Nikon Eclipse E600 microscope (Fryer Co., Huntley, IL). These micrographs were printed on 8µ Â 10µ paper and each margin defined so as not to allow any overlap. Each NFT and Pick body was circled and counted with the naked eye. Although counts were performed on immediately adjacent sections (sections 1 and 2 of the series), this approach limits identification of the same neurons with any degree of consistency. However, this approach should allow a good comparative estimate of the frequency of cells positive for the two stains. For ZnT-6/MC-1 double labeling experiments, images of 50 to 100 cells were captured from each case. Cells immunostained for ZnT-6 (green), MC-1 (red), and positive for both markers were counted with the naked eye. A representative section of MCI HPG was chosen to demonstrate overlap of ZnT-6 and TGN-38.
Statistical Analysis
Age and PMI were compared using a 2-tailed t-test and ABSTAT software (AndersonBell, Arvada, CO). Western blot results are expressed as mean T SEM % control band intensity and were compared using a 2-tailed t-test. Correlation analyses of ZnT-6 levels and Braak staging scores for MCI and AD subjects were carried out using ABSTAT software. Results of ZnT-6 immunostaining studies are reported as mean T SEM% NFT-positive, MC-1-positive or Pick body-positive neurons. Braak staging scores were compared using non-parametric testing and the MannWhitney U-test and results are expressed as the median.
RESULTS
Subject Demographics
Statistical comparison of age, PMI, and Braak scores for subjects analyzed in the Western blot analyses (Table 1) showed no significant differences in age or PMI between control, MCI or AD subjects. Braak staging scores for MCI (median = IV) and AD (median = VI) were significantly higher than for control subjects (median = II). Comparison of demographic data for subjects used in the immunohistochemical study (Table 2) showed there were no significant differences in age between control and AD subjects although PD subjects were significantly (p G 0.05) younger (66.3 T 0.8 years) and MCI subjects significantly (p G 0.01) older (92.0 T 1.6 years) than control subjects (81.0 T 1.5 years). Pick disease subjects showed a significantly higher PMI (9.5 T 3.0 hours) compared to control subjects (2.9 T 0.3 hours). There were no other significant differences in PMI. Braak staging scores were significantly higher in AD (median = VI) and MCI subjects (median = III) compared to controls (median = II). There were no differences in Braak scores for PD subjects compared to control subjects.
Verification of ZnT-6 Antibody Specificity and Western Blot Analyses
Our Western blot analyses of protein aliquots prepared from AD brain probed for ZnT-6 showed a predominant band at 51 kDa consistent with the molecular weight of ZnT-6 ( Fig. 1) . Immunostaining of the band was reduced by preincubation of the antibody with immunizing peptide (Fig. 1B) . Western blot analysis of MCI, AD and agematched control HPG showed a statistically significant (p G 0.05) elevation of ZnT-6 in AD subjects (205 T 30% control) compared to control subjects (100 T 30%). Analysis of HPG from MCI subjects showed a trend toward elevated ZnT-6 although the difference was not statistically significant ( Fig. 2A, B) . Correlation analyses of ZnT-6 levels and Braak staging scores for MCI and AD subjects showed a trend (p G 0.10) toward a significant positive relationship between ZnT-6 levels and Braak stage.
To further verify specificity of the antibody, sections of a representative AD patient were immunostained using antibody alone and antibody that had been pre-incubated with immunizing peptide. The immunizing peptide completely blocked ZnT-6 immunostaining confirming specificity of the antibody (Fig. 3) .
Alzheimer Disease
Sections immunostained with ZnT-6 antibody revealed staining of NFT-bearing neurons throughout CA1, subiculum (Fig. 4A) and the parahippocampal gyrus. Immunostaining was present in typical flame-shaped, globular and hemispiked NFT (Fig. 4A, arrow) . Rare ghost tangles were ZnT-6-positive but most were not stained. The staining suggested a filamentous nature of some NFT-bearing neurons, whereas in others a microgranular appearance was found. In some partially stained neurons, there was a granular character of the staining in the cytoplasm. The nuclei of NFTbearing neurons were not immunostained. Glial cells were not ZnT-6-positive. Neurites in a modest number of neuritic plaques were immunopositive for ZnT-6 (Fig. 4A, crossed  arrow) , although the number was much less than observed in the Bielschowsky-stained sections (Fig. 4B) . Amyloid did not stain nor did diffuse plaques. A few neuropil threads were positively stained with the ZnT-6 antibody. Counts of NFTbearing neurons on immediately adjacent sections stained with ZnT-6 and the modified Bielschowsky stain showed that ZnT-6 immunostained 89 T 7% (mean T SEM) of NFTbearing neurons stained with the Bielschowsky method.
Mild Cognitive Impairment
Confocal images of sections double labeled for ZnT-6 and TGN-38 showed that in normal neurons ZnT-6 colocalizes with TGN immunostaining in a perinuclear pattern (Fig. 5A Y C) . In contrast, cells expressing high levels of ZnT-6 throughout the cytoplasm show diminished TGN staining and loss of the typical perinuclear distribution observed in normal cells (Fig. 5A Y C) . Confocal microscopy of sections double labeled for MC-1 and ZnT-6 showed ZnT-6 immunostaining is generally low in neurons with minimal MC-1 immunoreactivity, suggesting low levels of the protein in normal neurons that are unlikely to be observed in sections stained using horseradish peroxidase conjugated secondary antibody. In contrast, neurons that were MC-1-positive showed pronounced immunostaining for ZnT-6. Counts of early NFT that were immunopositive for both ZnT-6 and MC-1 showed 85 T 4% of MC-1-positive cells were also strongly ZnT-6-immunopositive. Figure 6A shows ZnT-6-positive cells (green) that are MC-1-positive (Fig. 6B,  red) . Figure 6C is a merged image. Figure 7 shows that neurons with minimal ZnT-6 immunoreactivity (Fig. 7A ) also demonstrate low levels of MC-1 immunostaining (Fig. 7B,  arrows) . Cell identification is demonstrated by immunostaining with anti->-tubulin (Fig. 7C) . Figure 7D is a merged image. The block arrows show neurons with more pronounced ZnT-6 and MC-1 staining.
Pick Disease
In PD, immunostaining with ZnT-6 showed that abundant Pick bodies were positive in the granule neurons of the dentate gyrus, CA1, subiculum, and parahippocampal gyrus (Fig. 8A) . The overall regional pattern and staining of individual Pick bodies were similar in adjacent ZnT-6 and modified Bielschowsky-stained sections (Fig. 8B) . Most Pick bodies were seen as discreet, round, densely staining cytoplasmic inclusions with sharp borders filling much of the neuron cytoplasm. They were especially abundant in the granule neurons of the dentate gyrus. In the parahippocampal gyrus they were most prominent in lamina II. The nuclei of neurons containing Pick bodies showed no immunostaining. Counts of Pick bodies in the CA1 and subiculum of adjacent sections stained with ZnT-6 and the Bielschowsky stain showed that 100 T 19% of Pick bodies stained with the modified Bielschowsky stain were immunopositive for ZnT-6.
DISCUSSION
Our initial Western blot analyses showed significant elevations of ZnT-6 in the HPG of AD subjects and a trend toward elevated ZnT-6 in MCI compared to age-matched control subjects. To evaluate the cellular distribution of ZnT-6 in MCI, AD and PD, another tauopathy, we carried out immunohistochemical studies to determine if ZnT-6 immunostaining was increased in NFT-bearing neurons in AD or in Pick bodies in PD. To determine if ZnT-6 alterations occur early in the progression of AD, we also evaluated ZnT-6 immunostaining in the HPG of subjects with MCI. Our results demonstrate that the ZnT-6 immunostaining is substantially increased in 89 T 7% of NFT-bearing neurons in AD subjects, 85 T 4% of early NFT identified using the MC-1 antibody in MCI subjects, and 100 T 19% of Pick bodies in PD subjects. Our data also show neurites of a few neuritic plaques are immunopositive for ZnT-6. Confocal microscopy of sections of MCI HPG showed low levels of ZnT-6 immunostaining in neurons with minimal MC-1 immunoreactivity in a perinuclear pattern that colocalized with TGN staining suggesting basal ZnT-6 protein levels are relatively low in normal cells.
Although several studies have demonstrated elevations of Zn in the AD brain, there have been few studies of the transport proteins that function to maintain Zn homeostasis. In the brain, Zn occurs in three distinct pools including a membrane bound metalloprotein pool, an ionic pool of loosely bound ions in the cytoplasm, and a vesicular pool released during neurotransmission (33Y 37). Gray matter Zn concentrations range between 50 KM and 200 KM (8) with concentration gradients ranging from G 10 j9 M in the neuron cytoplasm to > 10 j3 M in synaptic vesicles (38) . During neurotransmission, Zn is released into the extracellular space and may reach concentrations in excess of 100 KM (21, 39), which are toxic to primary neuron cultures (4Y6).
Although Zn is essential for normal function of the brain, several studies show significant elevations of Zn in the AD brain, both at the bulk level (7 Y 13) and in senile plaques (40) . Additionally, vesicular Zn shows a regional distribution pattern that correlates well with the incidence of AD pathology (12, 41Y 43) .
Because the brain is subject to wide concentration gradients of Zn that can be neurotoxic, it is imperative that cells regulate Zn levels through control of influx and efflux and through chelation to sequestration proteins (19, 20, 33, 44 Y47) . In general, Zn homeostasis is maintained through three families of Zn binding proteins: metallothioneins I to IV (reviewed [17] ), ZIP proteins (15) , and Zn-transporters ZnT-1 through ZnT-7. Although there have been several studies of the role of metallothioneins in AD, our laboratory is the first to show significant alterations in ZnT proteins ZnT-1 and ZnT-4 in brain from subjects at various stages of AD (MCI, early and late stage) (48) .
ZnT-6 functions to sequester cytoplasmic Zn to the TGN and vesicular compartments during periods of elevated intracellular Zn (49) . In mice, ZnT-6 mRNA is present in liver, lung, kidney, spleen, heart, and brain. Western blot data from the present study demonstrate significantly elevated ZnT-6 in HPG of AD subjects and a trend toward elevated ZnT-6 in MCI. Correlation analyses of ZnT-6 levels and Braak staging scores demonstrate a trend toward a significant positive relationship between ZnT-6 and Braak score (p G 0.10). Because pathology in MCI is not uniform the presence of a positive relationship between Braak score and ZnT-6 levels may explain the subject to subject variability observed in MCI ZnT-6 Western blots. Immunohistochemical localization of ZnT-6 shows that elevated immunostaining is associated with neurons undergoing degeneration in AD and MCI as well as PD. Because ZnT proteins respond to alterations in intracellular Zn, increased ZnT-6 levels are consistent with studies showing elevated Zn in AD brain and suggest a compensatory increase in protein to redistribute excess intracellular Zn. Our previous study of ZnT-1 showed significantly decreased ZnT-1 in MCI, but significantly elevated levels of the protein in early and late stage AD HPG. Together these data support the hypothesis that the brain in AD is subject to elevated Zn and that there are attempts to redistribute the Zn.
The potential role of increased ZnT-6 in the degeneration of neurons in AD and PD is unclear. Preliminary studies of primary rat neuron cultures exposed to elevated Zn for 8 hours show a significant induction of ZnT-6 protein and a concomitant decrease of TGN-38 staining as a marker of the TGN. Confocal microscopy of exposed cells shows a pronounced fragmentation of TGN-38 staining from a perinuclear pattern to a disperse pattern of staining near the plasma membrane. The pattern of TGN-38 staining in neuron cultures that shows elevated ZnT-6 staining is comparable to that observed in NFT-bearing neurons in MCI and AD. Because the TGN functions to sort secretory proteins, lysosomal enzymes and plasma membrane proteins (50) , its disruption is likely to disrupt normal neuronal protein transport.
Previous studies show fragmentation of the Golgi apparatus in several neurodegenerative disorders including AD, amyotrophic lateral sclerosis (ALS), Creutzfeldt Jacob disease, and multiple system atrophy (51 Y53). Using animal models of ALS, Mourelatos et al showed increased Golgi fragmentation in spinal cord neurons of mice expressing mutant superoxide dismutase early in preclinical stages, and suggested a role for Golgi fragmentation in the observed neurodegeneration (54) . Cell culture studies show both prefibrillar aggregation of >-synuclein (55) and proteasome inhibition (56) lead to Golgi fragmentation. In addition, studies of Tarabal et al show motor neurons subjected to chronic NMDA treatment demonstrate alterations in Golgi apparatus that are long lasting and suggest that the protein transport system is a major target of sublethal excitotoxic injury in these cells (57) .
Overall, our data show most of the degenerating neurons (NFT and Pick bodies) identified by the modified Bielschowsky method in AD and PD also demonstrated increased ZnT-6 immunostaining. Our confocal microscopy studies show that substantially increased ZnT-6 immunostaining is present in the majority of early NFT identified using MC-1, a monoclonal antibody that identifies early conformational changes of tau only observed in AD brain, suggesting that ZnT-6 may play a role in the pathogenesis of NFT formation. Although speculative, our observation of a significant elevation of ZnT-6 in degenerating neurons suggests a pathway by which elevated Zn could accumulate in the TGN leading to disruption of normal sorting and trafficking of essential proteins and lipids and contribute to neuron degeneration and formation of cytoplasmic inclusions.
